Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice
Abstract The liver has a high regenerative ability and can induce spontaneous regression of fibrosis when early liver damage occurs; however, these abilities are lost when chronic liver damage results in decompensated cirrhosis. Cell therapies, such as mesenchymal stem cell (MSC) and macrophage ther...
Saved in:
Main Authors: | Shunsuke Nojiri (Author), Atsunori Tsuchiya (Author), Kazuki Natsui (Author), Suguru Takeuchi (Author), Takayuki Watanabe (Author), Yuichi Kojima (Author), Yusuke Watanabe (Author), Hiroteru Kamimura (Author), Masahiro Ogawa (Author), Satoko Motegi (Author), Takahiro Iwasawa (Author), Takeki Sato (Author), Masaru Kumagai (Author), Yui Ishii (Author), Tomomi Kitayama (Author), Yu-Tung Li (Author), Yuya Ouchi (Author), Takashi Shimbo (Author), Masaaki Takamura (Author), Katsuto Tamai (Author), Shuji Terai (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases
by: Atsunori Tsuchiya, et al.
Published: (2020) -
A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice
by: Satoko Motegi, et al.
Published: (2022) -
Mesenchymal stem cell therapies for liver cirrhosis: MSCs as "conducting cells" for improvement of liver fibrosis and regeneration
by: Atsunori Tsuchiya, et al.
Published: (2019) -
Transition of clinical and basic studies on liver cirrhosis treatment using cells to seek the best treatment
by: Shuji Terai, et al.
Published: (2021) -
Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases
by: Atsunori Tsuchiya, et al.
Published: (2017)